The role of mesenchymal stem cells in the treatment of ARDS and cytokine storms in COVID-19

Muhammad Waseem; Hamza Altaf; Nageen Hussain; Sobia Mushtaq; Samavia Siddique

doi:10.5281/zenodo.15733875

Authors

Muhammad Waseem Research Cell, University College of Medicine and Dentistry, University of Lahore, Pakistan https://orcid.org/0000-0002-0819-129X
Hamza Altaf Public Health, Department of Experimental Medicine, University of Campania Luigi Vanvitelli, Naples, Italy https://orcid.org/0000-0002-7573-6157
Nageen Hussain Institute of Microbiology and Molecular Genetics, University of the Punjab, Lahore, Pakistan https://orcid.org/0000-0002-4944-1881
Sobia Mushtaq University Institute of Biochemistry and Bio Technology-Pir Mehr Ali Shah Arid Agriculture University - PMAS AAUR, Rawalpindi, Pakistan https://orcid.org/0009-0001-2086-8304
Samavia Siddique Institute of Microbiology and Molecular Genetics, University of the Punjab, Lahore, Pakistan https://orcid.org/0009-0006-0043-7503

DOI:

https://doi.org/10.5281/zenodo.15733875

Keywords:

COVID-19, stem cell, mesenchymal stem cells, ARDS, cytokine storms

Abstract

The COVID-19 pandemic continues to challenge global healthcare systems, particularly due to the lack of effective treatment options for patients who develop acute respiratory distress syndrome (ARDS), cytokine storms, and long-term pulmonary complications. While antiviral agents and vaccines have mitigated some of the burden, these approaches are not universally effective—especially against emerging variants. In this context, mesenchymal stem cells (MSCs) have emerged as a promising therapeutic strategy due to their unique immunomodulatory and regenerative properties.

References

Xu R, Feng Z, Wang FS. Mesenchymal stem cell treatment for COVID-19. eBioMedicine. 2022;77:103920.

Karakaş N, Üçüncüoğlu S, Uludağ D, Karaoğlan BS, Shah K, Öztürk G. Mesenchymal stem cell-based COVID-19 therapy: bioengineering perspectives. Cells. 2022;11(3):465.

Li Z, Niu S, Guo B, Gao T, Wang L, Wang Y, et al. Stem cell therapy for COVID-19, ARDS and pulmonary fibrosis. Cell Prolif. 2020;53(12):e12939.

Choudhery MS, Harris DT. Stem cell therapy for COVID-19: possibilities and challenges. Cell Biol Int. 2020;44(10):2182–2191.

Bhaskar S, Sinha A, Banach M, Mittoo S, Weissert R, Kass JS, et al. Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper. Front Immunol. 2020;11:1648.

Liang B, Chen J, Li T, Wu H, Yang W, Li Y, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report. Medicine (Baltimore). 2020;99(31):e21429.

Golchin A, Seyedjafari E, Ardeshirylajimi A. Mesenchymal stem cell therapy for COVID-19: present or future. Stem Cell Rev Rep. 2020;16(3):427–433.

Li YR, Dunn ZS, Garcia G Jr, Carmona C, Zhou Y, Lee D, et al. Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention. Stem Cell Res Ther. 2022;13(1):112.

Harrell CR, Sadikot R, Pascual J, Fellabaum C, Jankovic MG, Jovicic N, et al. Mesenchymal Stem Cell-Based Therapy of Inflammatory Lung Diseases: Current Understanding and Future Perspectives. Stem Cells Int. 2019;2019:4236973.